Exscientia, a clinical-stage Artificial Intelligence (AI)-driven pharmatech company, today announced that it has won the Queen’s Award for Enterprise in Innovation, recognising its pioneering work in the field of AI-driven drug discovery.
Her Majesty the Queen has acknowledged the success of Exscientia’s AI-driven drug discovery platform, repeatedly taking new molecules from discovery to the clinic with unprecedented efficiency and with discovery times consistently under 12 months. Established in 2012, Exscientia is based in Oxford and Dundee with more than 125 employees across the UK, US and Japan.
Professor Andrew Hopkins, CEO and Founder of Exscientia, said “We are honoured to receive this Queen’s Award. It recognises the great strides that Exscientia is making in the AI-led drug discovery field. Our technology has resulted in the world’s first ever drugs designed using AI to enter Phase 1 testing for the treatment of OCD in collaboration with Sumitomo Dainippon and for immuno-oncology in partnership with Evotec. Winning this award is testament to the hard work, dedication and passion of our team, and I am delighted to accept it on their behalf.”
Now in its 55th year, the Queen’s Awards for Enterprise is the most prestigious business award in the country, with winning businesses able to use the esteemed Queen’s Awards Emblem.
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.